Hyperuricaemia: Another metabolic feature affecting the severity of chronic hepatitis because of HCV infection

Liver International

Volumn 32, Issue 9, 2012, Pages 1443-1450

  Petta, Salvatore ^a   Macaluso, Fabio S ^a   Cammà, Calogero ^a   Marco, Vito D ^a   Cabibi, Daniela ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic hepatitis C; Fibrosis; Steatosis; Uric acid

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; FATTY LIVER; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERURICEMIA; INSULIN BLOOD LEVEL; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; BIOPSY; FATTY LIVER; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PROGNOSIS; URIC ACID;

EID: 84865780054     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02842.x     Document Type: Article

References (38)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
2. Cammà C, Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol 2009; 50: 648-51.
3. Petta S, Muratore C, Craxì A. Non alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liv Dis 2009; 41: 615-25.
4. Cammà C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43: 64-71.
5. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41: 615-25.
6. Cammà C, Petta S, Di Marco V, et al. Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology 2009; 49: 195-203.
7. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
8. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-21.
9. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009; 21: 132-7.
10. Lonardo A, Loria P, Leonardi F, et al.; POLI.ST.E.N.A. Study Group. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002; 34: 204-11.
11. Li Y, Xu C, Yu C, et al. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009; 50: 1029-34.
12. Lee YJ, Lee HR, Lee JH, et al. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med 2010; 48: 175-80.
13. Yamada T, Suzuki S, Fukatsu M, et al. Elevated serum uric acid is an independent risk factor for nonalcoholic fatty liver disease in Japanese undergoing a health checkup. Acta Gastroenterol Belg 2010; 73: 12-7.
14. Xu C, Yu C, Xu L, et al. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS One 2010; 5: e11578.
15. Ryu S, Chang Y, Kim SG, et al. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism 2011; 60: 860-6.
16. Lee JW, Cho YK, Ryan M, et al. Serum uric acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver 2010; 4: 378-83.
17. Petta S, Cammà C, Cabibi D, et al. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 34: 757-66.
18. Afzali A, Weiss NS, Boyko EJ, et al. Association between serum uric acid level and chronic liver disease in the United States. Hepatology 2010; 52: 578-89.
19. Grassi A, Ballardini G, Susca M, et al. HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3? Aliment Pharmacol Ther 2005; 2: 79-82.
20. Pellicano R, Puglisi G, Ciancio A, et al. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection? J Med Virol 2008; 80: 628-31.
21. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. American diabetes association: clinical practice recommendations 2000 committee report. Diabetes Care 2000; 23: S4-19.
22. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
23. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National health and nutrition examination survey. JAMA 2000; 283: 2404-10.
24. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-83.
25. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluric acidtion of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
26. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
27. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
28. SAS Technical Report, SAS/STAT software: changes and enhancement, Release 6.07. Cary, NC: SAS Institute, Inc., 1992.
29. Petta S, Amato M, Cabibi D, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010; 52: 1543-52.
30. Castéra L, Hézode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
31. Everhart JE, Lok AS, Kim HY, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009; 137: 549-57.
32. Yamada T, Fukatsu M, Suzuki S, et al. Elevated serum uric acid predicts impaired fasting glucose and type 2 diabetes only among Japanese women undergoing health checkups. Diabetes Metab 2011; 37: 252-8.
33. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303.
34. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011; 60: 1258-69.
35. Zografos TA, Liaskos C, Rigopoulou EI, et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol 2008; 103: 605-14.
36. Abdelmalek MF, Lazo M, Horska A, et al. Higher dietary fructose is associated with impaired hepatic ATP homeostasis in obese individuals with type 2 diabetes. Hepatology 2012; Mar 29. DOI: 10.1002/hep.25741.
37. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
38. Leandro G, Mangia A, Hui J, Fabris P, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individuric acidl patient data. Gastroenterology 2006; 130: 1636-42.